Researchers from the University of Cambridge announced a breakthrough in Alzheimer's disease research in September 2024: a new drug in clinical trials has shown potential to slow down the progression of Alzheimer's by targeting protein accumulation, one of the primary contributors to neurodegeneration, which could become the first treatment to effectively slow Alzheimer's progression if successful.